CUPE 3550 President Mandy Lamoureux will be available for media questions at Ross Shepard High School tomorrow at 7:15 am, ahead of the strike by Edmonton Public Schools and Sturgeon Public Schools staff. Picket lines will begin at 7:30 am MST at various locations, including Ross Shepard, M. E. LaZerte, and Elder Dr. Francis Whiskeyjack High Schools for Local 3550, and all schools for Local 4625.
Edison International and Southern California Edison (SCE) are addressing life-threatening conditions caused by powerful winds and wildfires in Southern California. As of January 12, SCE restored power to over 500,000 customers, with efforts ongoing despite severe equipment damage. Two Electric Safety Incident Reports (ESIRs) were filed for the Eaton and Hurst Fires, which are under investigation for potential links to SCE equipment. To support wildfire relief, Edison International has pledged $1 million to community organizations. Power restoration efforts prioritize safety amid challenging weather conditions expected to continue through January 15.
Bronstein, Gewirtz & Grossman, LLC announces a class action lawsuit against BioAge Labs, Inc. (NASDAQ: BIOA) and certain officers for alleged violations of federal securities laws related to the company’s September 2024 IPO. The lawsuit cites BioAge’s announcement on December 6, 2024, of the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which caused the stock price to plummet from $20.09 to $4.65 per share. Investors who suffered losses are encouraged to join the lawsuit before the March 10, 2025, lead plaintiff deadline.
Revvity, Inc. (NYSE: RVTY) will release its Q4 and full-year 2024 financial results on January 31, 2025, before market opening. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak will follow at 8:00 a.m. ET. Preliminary Q4 results indicate 5% reported revenue growth and 6% organic growth, with total revenue projected at $730 million. Full-year 2024 adjusted EPS is expected to meet or exceed prior guidance. Prahlad Singh will also present at the J.P. Morgan Healthcare Conference on January 13, 2025. The company highlights the use of non-GAAP financial measures for a clearer understanding of operational trends.
Vertex Pharmaceuticals announced updates ahead of its January investor meetings, including its presentation at the 43rd J.P. Morgan Healthcare Conference. Key highlights include the approval of ALYFTREK and expanded use of TRIKAFTA for cystic fibrosis, regulatory approval for CASGEVY for sickle cell disease and beta thalassemia, and advancements in clinical trials for acute pain, kidney diseases, type 1 diabetes, and myotonic dystrophy. Vertex also reported expanded treatment access and updated epidemiology for cystic fibrosis and type 1 diabetes. The company continues to broaden its global presence and innovate across its pipeline, with pivotal trial data expected in 2025.
Copyright © Todas las marcas son propiedad de la respectiva empresa o de BORGES MEDIA INC. Queda prohibida la reproducción total o parcial de cualquiera de los contenidos que aquí aparecen, así como su traducción a cualquier idioma sin autorización escrita de su propietario, la mejor revista de Sacramento. Consulte nuestra Política de Privacidad.
